Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)
Clinical and research applications include: Primary carnitine deficiency Dialysis patients (carnitine is lost during treatment) Mitochondrial disorders Performance and body composition For Canadians exploring metabolic optimization, injectable L-carnitine remains one of the more well-studied and accessible compounds available
BioInfinity is our preferred overall supplier because it offers 5 mg, 10 mg, and 20 mg quantities at approximately $8 per milligram, along with a current batch-specific COA and HPLC-UV/MS testing
Clinical Characteristics of COVID-19 in New York City
